Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.

NCT01229280 is registered in ClinicalTrials.gov with Center for Clinical Pharmacology Research Bdbeq S.A. as lead sponsor.

NCT NCT01229280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01229280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.
Lead sponsor
Center for Clinical Pharmacology Research Bdbeq S.A.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2010
Completion date
February 28, 2011
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalency